Search

296 Result(s)
Sort by

COVID-19 In Colombia we support integrally

COVID-19 In Colombia we support integrally

At Boehringer Ingelheim Colombia, we are caring for those in the most vulnerable situations during COVID-19. Click here to learn more about our work.
Heart Diseases

Heart Diseases

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide.
1885-1948

1885-1948

In 1885, Albert Boehringer purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim. Click here to learn more about our history.
Thelaziosis dog eyeworms

Thelaziosis dog eyeworms

Most pet owners probably do not associate the scientific name “thelaziosis” to eyeworm infestations experienced by their dogs. Click here to learn more.
Partnering for innovation and growth

Partnering for innovation and growth

In this interview Dr Frerich de Vries talks about why partnerships are one of the key areas of interest for Boehringer Ingelheim and more. Learn more.
Companion Animals

Companion Animals

Boehringer Ingelheim Animal Health helps provide longer, healthier and happier lives for companion animals. Click here to learn and find out more.
COVID-19 Material donations in Germany

COVID-19 Material donations in Germany

Boehringer Ingelheim donates protective equipment and disinfectants to authorities and social institutions at the company's German sites during COVID-19.
Our Contribution

Our Contribution

Humanity is facing serious challenges. We believe we can always do more – for ourselves and for the generations to come. Click here to find out more.
Cat vaccination 10 things you should know

Cat vaccination 10 things you should know

We’ve answered 10 important questions about cat vaccination, to help you make informed decisions about preserving your cat’s health. Read more here.
Our Expectations

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners. Click here to learn more.
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Lyon

Lyon

Boehringer Ingelheim has a research and production network across the globe. Click here to read and find out information about our Lyon site.
COVID-19 General Q&A

COVID-19 General Q&A

Here we provide a list of questions and answers about COVID-19, including what it is, how it spreads, and more. Click here to find out more.
Circular economy

Circular economy

Plastic pollution is one of the most serious threats to the world’s oceans. Click here to find out how long it takes for garbage to dissolve in the oceans!
Our Partnering Culture

Our Partnering Culture

We embrace the power of partnerships and alliances to find even more breakthrough therapies that change lives. Find out more about our partnering culture.
Stem cells a new frontier

Stem cells a new frontier

Stem cells may be a game changer for the development of new veterinary treatments. Click here to read this story and find out more information.
COVID-19 Joining forces against COVID-19

COVID-19 Joining forces against COVID-19

While the challenges posed by the COVID-19 pandemic are massive, so are the good examples of corporate citizenship arising all over the world. Learn more.
REACH / GHS / Material safety data sheets

REACH / GHS / Material safety data sheets

European and international chemical legislations like REACH and GHS impact Boehringer Ingelheim's activities in many different ways. Learn more here.
More Potential

More Potential

Continuing a journey that began more than 135 years ago, Boehringer Ingelheim steps up its commitment to sustainable development. Find out more here.
COVID-19 IMI2–Call 21

COVID-19 IMI2–Call 21

CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.